Filing Flows › Bioventus (BVS) › Q3 2025
Bioventus (BVS) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 4, 2025
Bioventus (BVS) reported revenue of $139M for the third quarter 2025 (Q3 2025), -0.2% from a year earlier and -6% from the quarter before. Operating margin was 8.1%, net earnings $3.2M (2.3% of revenue).
Bioventus, Q3 2025: revenue $139M (-0.2% year over year), operating margin 8.1%, net earnings $3.2M, operating cash flow $30.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $139M | -6% | -0.2% |
| Gross profit | $94.2M | -8% | +0.7% |
| Operating profit | $11.3M | -39% | +209% |
| Net earnings | $3.2M | -58% | — |
| Operating cash flow | $30.1M | +16% | +192% |
| Free cash flow | $29.6M | +17% | +189% |
What changed
Revenue was $138.7M in Q3 2025, roughly flat year over year and down 6% from the previous quarter.
Gross margin was 68.0%, up 0.6 points from a year earlier. Operating profit was $11.3M, a 8.1% margin (up 5.5 points year over year). Operating expenses fell 8% while revenue was flat. Net earnings were $3.2M. The effective tax rate was 14.2%.
Operating cash flow was $30.1M (up 192% year over year), 751% of net income including minority interests. Non-cash charges added back $11.4M of depreciation and amortization and $3.2M of share-based compensation. Working capital and other items added $11.5M. Capital expenditures of $473K left free cash flow of $29.6M.
Questions
What was Bioventus' revenue in the third quarter 2025?
Bioventus (BVS) reported revenue of $139M for the third quarter 2025 (Q3 2025), -0.2% from a year earlier and -6% from the quarter before.
Was Bioventus profitable in the third quarter 2025?
Operating profit was $11.3M (8.1% of revenue) and net earnings $3.2M.
Source: Bioventus 10-Q on SEC EDGAR.